The impact of rescue or maintenance therapy with EGFR TKIs for Stage IIIb-IV non-squamous non-small-cell lung cancer patients requiring mechanical ventilation

@inproceedings{Hsia2014TheIO,
  title={The impact of rescue or maintenance therapy with EGFR TKIs for Stage IIIb-IV non-squamous non-small-cell lung cancer patients requiring mechanical ventilation},
  author={Te-chun Hsia and Chih-Yen Tu and Hung-Jen Chen},
  booktitle={BMC Anesthesiology},
  year={2014}
}
BackgroundThe toxicity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is less than that of cytotoxic agents. The reports of dramatic response and improvement in performance status with the use of EGFR TKIs may influence a physician’s decision-making for patients with non-squamous non-small cell lung cancer (NSCLC) and life-threatening respiratory distress. The aim of this study was to evaluate the outcome of rescue or maintenance therapy with EGFR TKI for stage… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

Toxicity and response criteria of the Eastern Cooperative Oncology Group.

  • American journal of clinical oncology
  • 1982
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
VIEW 2 EXCERPTS